The San Francisco based biopharmaceutical company Medivation has recently published results of its first pivotal clinical trial of Dimebon in Alzheimer’s disease. Dimebon, a drug formerly approved as an allergy treatment, demonstrated statistically significant improvement over placebo in memory, thinking, ...